Drug Profile
EDIT 101
Alternative Names: AGN 151587; EDIT-101Latest Information Update: 11 Jan 2023
Price :
$50
*
At a glance
- Originator Editas Medicine
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Cep290 protein modulators; Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Leber congenital amaurosis
Highest Development Phases
- Phase I/II Leber congenital amaurosis
Most Recent Events
- 09 Jan 2023 EDIT 101 is available for licensing as of 09 Jan 2023. http://www.editasmedicine.com 9378305
- 31 Dec 2022 Editas Medicine terminates the phase I/II BRILLIANCE trial in Leber congenital amaurosis (In adults, In children, In adolescents, In the elderly) in USA (Intraocular)
- 17 Nov 2022 Efficacy and adverse events data from a phase I/II BRILLIANCE trial in Leber congenital amaurosis released by Editas Medicine